KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.

Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, Dirk Schadendorf, Genevieve Boland, Jeffrey Weber, Karl D Lewis, Daniel Johnson, Gareth Rivalland, Adnan Khattak, Margarita Majem, Helen Gogas, Georgina V Long, Sue L Currie, David Chien, Mary A Tagliaferri, Matteo S Carlino, Adi Diab

Future Oncol 18(8) 903-913

PMID35073733
PMCID-
DOI10.2217/fon-2021-1286
发表日期2022-01-25
摘要

摘要

Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. PIVOT-02 showed that BEMPEG plus NIVO was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma. PIVOT-12 is a randomized, phase III, global, multicenter, open-label study comparing adjuvant therapy with BEMPEG plus NIVO versus NIVO alone in adult and adolescent patients with completely resected cutaneous stage III/IV melanoma at high risk of recurrence. The primary objective is to compare the efficacy, as measured by recurrence-free survival, of BEMPEG plus NIVO versus NIVO.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。